Arrowgrass Capital Partners (US)’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
Arrowgrass Capital Partners (US)'s PFE Position: Q4 2019 in Review
Arrowgrass Capital Partners (US) increased its Pfizer (PFE) stake by 4.6% in Q4 2019, buying an estimated $234K and bringing the position to 149,660 shares worth $5.56M. The position accounts for 1.46% of the portfolio, ranked #25.
Arrowgrass Capital Partners (US) first reported a position in PFE in Q2 2014 and has held it in 17 quarters since. The position peaked at $41M in Q4 2015. 2,525 funds tracked by Wall St. Rank hold PFE as of Q4 2019.
- Arrowgrass Capital Partners (US) held 149,660 shares of Pfizer worth $5.56M as of Q4 2019.
- Arrowgrass Capital Partners (US) bought 6,575 Pfizer shares in Q4 2019, an estimated $234K.
- Pfizer made up 1.46% of Arrowgrass Capital Partners (US)'s portfolio in Q4 2019, its #25 holding.
- Arrowgrass Capital Partners (US) first reported a position in Pfizer in Q2 2014 and has held it in 17 quarters since.
- Arrowgrass Capital Partners (US)'s Pfizer position peaked at $41M in Q4 2015.
- 2,525 funds tracked by Wall St. Rank held Pfizer as of Q4 2019.
Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.